leisure time -WSS

leisure time

author：hotspot 2025-10-04 03:59:35 - browse：31548

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Ending health disparities requires full federal government, panel says

focus

WSS

Ford recalls 870K F

Pharmacists can make shortage drugs, but at what cost?

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

VC firm RA Capital starts a new synthetic biology incubator

NIH confirmation hearing shows politicization of research

STAT Summit: Biotech founders on deal

leisure time

leisure time

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

CEOs share strategies for surviving biotech slump

United colonoscopy coverage change 'may cost lives,' doctors say

CEOs share strategies for surviving biotech slump

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Timeline: Special counsel's probe into Trump's handling of classified documents

Medical leaders decry Supreme Court decision on affirmative action

FDA gives detailed accounting of AI

Medicare details structure of new drug price negotiation program

Public health communication lessons from Covid

hotspot

Marc Tessier

Senate committee scrutinizes Medicare Advantage brokers

Alexander Hamilton and the argument for universal insurance

Senate committee scrutinizes Medicare Advantage brokers

STAT Summit: Biotech founders on deal

The EU Joint Clinical Assessment needs to live up to its promise

hotspot

knowledge

focus

hotspot